ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch? (Seite 330)
eröffnet am 07.08.14 10:02:11 von
neuester Beitrag 25.04.24 20:55:29 von
neuester Beitrag 25.04.24 20:55:29 von
Beiträge: 10.979
ID: 1.197.187
ID: 1.197.187
Aufrufe heute: 24
Gesamt: 1.133.868
Gesamt: 1.133.868
Aktive User: 0
ISIN: CA03879J1003 · WKN: A14XMD · Symbol: I9DN
2,5400
EUR
-1,01 %
-0,0260 EUR
Letzter Kurs 25.04.24 Tradegate
Neuigkeiten
18.04.24 · globenewswire  |
10.04.24 · wO Chartvergleich |
04.04.24 · globenewswire |
08.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 12,800 | +17,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 70.090.016 von Mammuste am 01.12.21 19:08:00Ich mit kleiner Posi. Aber wenig Handel in Deutschland.
In Anbetracht der Knallermeldung ist die aktuelle Kursentwicklung ziemlich bescheiden. Besonders aktuell, wo sie anscheinend von den Shorties schon wieder ordentlich runtergedrückt wird. Aber ich könnte mir gut vorstellen, dass ABUS die nächsten Tage immer mehr ins Licht der Medien gerät und die Aktie dann noch mal nachzündet. Wird auf alle Fälle schon jetzt spannend, wo ABUS morgen eröffnen wird - unabhängig vom heutigen Schlusskurs. Gap up könnte könnte sein.
einen kleinen aber feinen Rücksetzer wird es vielleicht geben, dann bin ich dabei.
ansonsten Gratulation an alle, die drin sind, ich hatte Arbutus nie so richtig beobachtet, Fehler ...
ansonsten Gratulation an alle, die drin sind, ich hatte Arbutus nie so richtig beobachtet, Fehler ...
Dec 1 (Reuters) - Moderna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp .
Arbutus shares nearly doubled following the ruling, up 95% at $6.25. Moderna shares were off more than 10% at $316.43.
The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.
Moderna and Arbutus did not respond to requests for comment.
Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.
The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.
Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.
"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna," he said.
Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.
Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.
The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd . Roivant owns about 80% of Genevant and Arbutus owns the remainder.
Arbutus shares nearly doubled following the ruling, up 95% at $6.25. Moderna shares were off more than 10% at $316.43.
The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.
Moderna and Arbutus did not respond to requests for comment.
Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.
The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.
Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.
"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna," he said.
Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.
Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.
The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd . Roivant owns about 80% of Genevant and Arbutus owns the remainder.
Ist eigentlich noch jemand bei Roivant dabei?
Trading Spotlight
Antwort auf Beitrag Nr.: 70.089.794 von ChrisHamburg01 am 01.12.21 18:54:03Naja, ich hab ein Durchschnitt von 0,80. Also hatte ich den Sprung bei netlist schon.
Antwort auf Beitrag Nr.: 70.089.392 von Takado am 01.12.21 18:25:02
Es wäre schön wenn Netlist auch mal so einen Sprung macht.
Zitat von Takado: Bin hier heute auch wieder beim Dip rein. Nicht so groß wie bei netlist, aber immerhin.
Es wäre schön wenn Netlist auch mal so einen Sprung macht.
Antwort auf Beitrag Nr.: 70.089.620 von Berti1111 am 01.12.21 18:41:36
Allein der derzeitige "Werbeffekt" in der Presse, kombiniert mit dem HBV Produktportfolio ist hunderte Mio wert.
Zitat von Berti1111: Da wird es bald wieder dumme Gesichter geben wenn der Kurs wie ein Stein wieder runterfällt.
Allein der derzeitige "Werbeffekt" in der Presse, kombiniert mit dem HBV Produktportfolio ist hunderte Mio wert.
Da wird es bald wieder dumme Gesichter geben wenn der Kurs wie ein Stein wieder runterfällt.
Wir sind übrigens schon im Bildticker... 18.12 Uhr
https://www.bild.de/news/inland/news-inland/corona-news-im-l…
https://www.bild.de/news/inland/news-inland/corona-news-im-l…
Durchsuchen
ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch?
